Form 4: Carisma Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
David Scadden, a director of Carisma Therapeutics Inc., acquired stock options for 38,700 shares on July 1, 2024.
Summary
- On July 1, 2024, David Scadden, a director of Carisma Therapeutics Inc., acquired stock options.
- The options grant the right to buy 38,700 shares of common stock at an exercise price of $1.67 per share.
- The options vest over three years in equal monthly installments, starting July 1, 2024, contingent upon continued service to Carisma Therapeutics Inc.
- The options expire on July 1, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment. It's a standard insider transaction. The acquisition of options by a director can be seen as a mildly positive signal, but it's not a major event.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of the transaction: David Scadden acquired stock options. |
| 07/01/2024 | Vesting start date: Options vest monthly over three years. |
| 07/01/2034 | Expiration date: Options expire. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.